Detalhe da pesquisa
1.
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
Rheumatology (Oxford)
; 58(1): 70-79, 2019 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30137547
2.
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Clin Immunol
; 191: 10-20, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29518577
3.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artigo
Inglês
| MEDLINE | ID: mdl-28629665
4.
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Nat Biotechnol
; 25(11): 1256-64, 2007 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-17989688
5.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
N Engl J Med
; 355(12): 1233-43, 2006 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-16990386
6.
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Arthritis Rheumatol
; 71(5): 685-695, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30427585
7.
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
N Engl J Med
; 350(6): 552-9, 2004 Feb 05.
Artigo
Inglês
| MEDLINE | ID: mdl-14762182
8.
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Arthritis Rheumatol
; 69(10): 1969-1977, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28845577
9.
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Circulation
; 108(10): 1176-83, 2003 Sep 09.
Artigo
Inglês
| MEDLINE | ID: mdl-12925455
10.
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Ann Thorac Surg
; 77(3): 942-9; discussion 949-50, 2004 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-14992903
11.
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
JAMA
; 291(19): 2319-27, 2004 May 19.
Artigo
Inglês
| MEDLINE | ID: mdl-15150203
12.
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study.
Eur Heart J
; 27(11): 1289-97, 2006 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-16611669
13.
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
Blood
; 106(7): 2559-65, 2005 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15985537
14.
Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis.
J Rheumatol
; 31(8): 1588-97, 2004 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-15290740